Umbilical Stem Cells and Wharton’s Jelly: What the Science Really Shows

Umbilical stem cells and Wharton’s Jelly products are often advertised as powerful regenerative therapies for joint pain, arthritis, and sports injuries. You may see clinics promoting “umbilical stem cell injections” or “Wharton’s Jelly stem cell treatments” for orthopedic conditions.

But what does the actual scientific research show?

Several well-designed laboratory studies have carefully examined these products to see whether they truly contain living stem cells. The results are surprisingly consistent—and important for patients to understand.

What Are Umbilical Stem Cells and Wharton’s Jelly?

Umbilical tissue comes from the umbilical cord after birth, which contains a gelatin-like substance called Wharton’s Jelly. This tissue naturally contains mesenchymal stem cells (MSCs) when it is fresh.

Because of this, some companies process umbilical cord tissue and sell injectable products that are marketed as umbilical stem cells or Wharton’s Jelly stem cells.

However, once these tissues are processed, stored, frozen, and sterilized, an important question arises:

Do these products still contain living stem cells by the time they reach the patient?

Multiple studies have examined this exact question.

Study #1: Placental Tissue Products and Cell Viability

A laboratory study presented by Berger, Lyons, and Steinmetz (2015) evaluated several injectable placental and amniotic tissue products commonly used in orthopedic medicine.

Researchers tested whether the products contained living cells capable of growth and repair.

The findings were clear:

• The products contained structural proteins and growth factors
  
  
• No living stem cells were detected
  
  
• The tissues were largely acellular (cell-free) after processing
  
  

This suggests that while these products may contain biologic molecules, they do not function as living stem cell therapies.

Study #2: Do Amniotic Fluid Products Contain Stem Cells?

A study published in the American Journal of Sports Medicine by Panero and colleagues (2019) directly investigated whether amniotic fluid products marketed as stem cell therapies actually contain mesenchymal stem cells.

Researchers compared these products to bone marrow aspirate, which is known to contain living MSCs.

The results showed:

• No mesenchymal stem cells were found in the amniotic fluid products
  
  
• No cells were able to grow or form colonies in culture
  
  
• Bone marrow samples did contain viable stem cells, as expected
  
  

The authors concluded that these products should not be described as stem cell therapies.

Study #3: Proteins vs Living Cells in Amnion Products

Another investigation presented at the Orthopedic Research Society Annual Meeting analyzed nine commercially available amnion-derived biologic products.

The study evaluated:

• Cell viability
  
  
• Protein content
  
  
• Growth factors
  
  

The findings showed that while these products contained biologic proteins, the cell viability was extremely low or absent.

This means the products may act as biologic scaffolds or signaling molecules, but they do not deliver living regenerative stem cells.

Study #4: Umbilical Cord Allografts vs Autologous Orthobiologics

A 2021 study in the American Journal of Sports Medicine by Berger, Centeno, and colleagues examined commercial umbilical cord tissue products and compared them to autologous orthobiologic treatments such as bone marrow.

Researchers tested whether the products could form colony-forming units, a key sign that living stem cells are present.

The results showed:

• No colony-forming stem cells were detected in the commercial umbilical cord products
  
  
• Protein composition varied widely between products
  
  
• Autologous bone marrow samples did contain viable stem cells capable of growth
  
  

The authors concluded that commercially available umbilical cord allografts do not appear to contain functional stem cells.

What This Means for Patients

The research across multiple studies shows a consistent pattern:

Most commercially available umbilical stem cell or Wharton’s Jelly injections do not contain living stem cells by the time they reach the clinic.

Instead, they may contain:

• Structural proteins
  
  
• Growth factors
  
  
• Extracellular matrix components
  
  

These substances may still have biologic effects, but they are not the same as living stem cell therapies.

The Difference Between Donor Products and Your Own Cells

In regenerative medicine, there is an important distinction between:

Allogeneic products (donor tissue)

• Processed and stored before use
  
  
• Often lack living cells after sterilization and freezing
  
  

Autologous biologics (your own cells)

• Collected from your body at the time of treatment
  
  
• Contain living cells and growth factors
  
  

Because of this difference, many physicians prefer autologous regenerative therapies, which preserve cell viability.

The Bottom Line on Umbilical Stem Cells

Umbilical cord tissue and Wharton’s Jelly are fascinating biologic materials with potential uses in medicine. However, current research suggests that most commercial umbilical stem cell injections do not contain living stem cells.

Patients considering regenerative medicine should understand:

• Not all biologic injections are true stem cell therapies
  
  
• Scientific evidence matters when evaluating treatment claims
  
  
• The source and processing of a biologic product strongly influence its effectiveness
  
  

A careful evaluation with a physician experienced in regenerative medicine can help determine which options are most appropriate for your condition.

Educational Disclaimer:
This article is for educational purposes only and is not medical advice. Treatment options should always be discussed with a qualified physician who can evaluate your individual medical condition.

‍